NEW DELHI: The initial public offering (IPO) of Anthem Biosciences Ltd was fully subscribed by the second day of bidding on Tuesday.
As per NSE data available till 10:54 am, the IPO received bids for 5,24,97,042 shares against 4,40,70,682 shares on offer, translating to a subscription rate of 1.19 times.
The non-institutional investors’ category saw 2.94 times subscription, while the retail individual investors (RIIs) portion was subscribed 91%. The quota reserved for qualified institutional buyers (QIBs) was subscribed 38%.
Anthem Biosciences has already raised ₹1,016 crore from anchor investors.
The ₹3,395-crore IPO of the Bengaluru-based company is set to close on Wednesday. The price band for the issue is ₹540–570 per share.
Since the entire IPO is an offer for sale (OFS), the company will not receive any proceeds; all funds will go to the selling shareholders.
Anthem operates as a Contract Research, Development and Manufacturing Organization (CRDMO), offering end-to-end services across drug discovery, development, and production. It also manufactures and markets complex fermentation-based Active Pharmaceutical Ingredients (APIs) such as probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.
The issue is being managed by JM Financial, Citigroup Global Markets India, J.P. Morgan India, and Nomura Financial Advisory and Securities (India) as the book-running lead managers.
